For anyone in Meade searching for CJC-1295, the foundational reality is that this compound is available only through an online research supply market. What this means for Meade researchers is that your location matters far less than your ability to evaluate vendor quality — and those verification methods are accessible to anyone. A properly operating CJC-1295 supplier's COA must contain HPLC purity, mass spectrometry confirmation of molecular identity, bacterial endotoxin testing, and a residual solvents panel — all batch-matched to your order. This guide walks Meade researchers through that evaluation process and explains what quality documentation for CJC-1295 should look like.
CJC-1295: What the Research Shows
CJC-1295 belongs to the growth hormone secretagogue (GHS) class, compounds that stimulate pulsatile growth hormone release by acting on the ghrelin receptor (GHSR-1a) or growth hormone releasing hormone (GHRH) receptor. Ipamorelin, GHRP-2, GHRP-6, and Hexarelin all work primarily through GHSR-1a agonism, producing GH pulses with varying specificity profiles. CJC-1295 and Sermorelin work through the GHRH receptor, mimicking the natural hypothalamic signal for GH release. The downstream effect in both cases is increased pulsatile GH secretion and subsequent IGF-1 production in the liver. For researchers in Meade studying the GH-IGF-1 axis, this mechanistic clarity makes the GHS class a productive experimental tool.
How to Evaluate CJC-1295 Vendors
The most reliable path to quality CJC-1295 is community research first — peptide forums track vendor quality over time that are more accurate than commercial vendor claims. Endotoxin testing in the COA is essential for any injectable research use — endotoxins from gram-negative bacterial contamination can trigger dangerous inflammatory cascades even at minute levels. Negative indicators in CJC-1295 vendor evaluation: prices more than 30-40% below standard market rates, unclear production details, no community presence, and COAs that omit endotoxin testing. The powdered lyophilised form of CJC-1295 is much more stable than liquid pre-made solutions — lyophilised powder stays viable for years at −20°C, while liquid preparations break down rapidly even under refrigeration.
Order CJC-1295 — ships to Meade
COA-verified · International tracking · Research grade
Research compound status for CJC-1295 means risk characterisation relies on animal studies, in-vitro work, and limited human observations — rather than the large-scale clinical data that informs approved drug safety. Lyophilised CJC-1295 should be stored frozen (−20°C) immediately upon receipt; avoid repeatedly thawing and refreezing reconstituted peptide by dividing into single-dose aliquots before freezing. Verify the endotoxin level in your CJC-1295 batch COA before use in any in-vivo protocol — look for results expressed as EU/mg or EU/mL and compare against acceptable research limits for your application. For any individual considering CJC-1295 outside a formal research context: seek medical advice first — this compound is unapproved for human therapeutic application and its safety characterisation does not match that of regulated drugs.
Frequently Asked Questions
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
